Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score.

Gabriel Bsteh Harald HegenKatharina RiedlPatrick AltmannMichael AuerKlaus BerekFranziska Di PauliRainer EhlingBarbara KornekTobias MonscheinWalter RinnerChristiane SchmiedSebastian WurthKarin ZebenholzerAnne ZinganellTobias ZrzavyGudrun ZulehnerFlorian DeisenhammerPaulus Stefan RommerFritz LeutmezerThomas Berger

Published in: European journal of neurology (2021)

The composite VIAADISC score is a valuable tool to inform and support patients and neurologists in the process of decision making to discontinue injectable DMTs.

Keyphrases

multiple sclerosis
end stage renal disease
decision making
chronic kidney disease
newly diagnosed
ejection fraction
prognostic factors
peritoneal dialysis
dendritic cells
immune response
white matter
hyaluronic acid
patient reported